drugset / Trial / NCT02143401
Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
This phase I trial studies the side effects and the best dose of navitoclax when given together with sorafenib tosylate in treating patients with solid tumors that have returned (relapsed) or do not respond to treatment (refractory). Navitoclax and sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Timeline
- Start
- 2015-01-30
- Primary completion
- 2022-11-30
- Completion
- 2024-03-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Navitoclax | Small molecule | — | Oral |
| Background | Sorafenib | Small molecule | — | Oral |